Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525061 | 0.90 | ELANE (0.74) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL524078 | 0.89 | ELANE (0.64) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL597440 | 0.88 | ELANE (0.63) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL595623 | 0.87 | ELANE (0.60) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL2695330 | 0.87 | ELANE (0.65) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL1603348 | 0.86 | ELANE (0.65) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL14922192 | 0.86 | ELANE (0.61) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL597096 | 0.86 | ELANE (0.61) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| Azd-6553 SCHEMBL3705053 | 0.86 | ELANE (0.64) | ELANEMEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL597381 | 0.86 | ELANE (0.62) | ELANEMEN1KMT2ACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | claimed |
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | claimed |
| US-8410114-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8114881-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | ELANE 2/4885MEN1 3824/4885KMT2A 4493/4885 |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | ELANE 2/4885MEN1 3824/4885KMT2A 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.